Abstract
To evaluate whether S100A11 could be considered to be a novel diagnostic marker in breast carcinoma, the method of differential proteomics, Western blotting, and immunohistochemistry were used to detect the expression pattern and subcellular localization of S100A11. Statistical analyses indicated that specific up-regulated of A100A11 did not correlate with other prognostic factors such as age, tumor size, grade and stage, ER, PR, HER-2 and nodal status. Our data support that S100A11 is a novel diagnostic marker in breast carcinoma. Analysis of S100A11 expression in breast cancer may be an effective tool help in detection of early-stage breast cancer.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Amino Acid Sequence
-
Biomarkers, Tumor / analysis*
-
Blotting, Western
-
Breast Neoplasms / chemistry*
-
Breast Neoplasms / pathology
-
Carcinoma, Ductal, Breast / chemistry*
-
Carcinoma, Ductal, Breast / pathology
-
Chi-Square Distribution
-
Electrophoresis, Gel, Two-Dimensional
-
Female
-
Humans
-
Immunohistochemistry
-
Middle Aged
-
Molecular Sequence Data
-
Neoplasm Staging
-
Predictive Value of Tests
-
Prognosis
-
Proteomics / methods
-
S100 Proteins / analysis*
-
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
-
Up-Regulation
Substances
-
Biomarkers, Tumor
-
S100 Proteins
-
S100A11 protein, human